Event Intelligence
Dallah Health appoints Muteab Altukeas as CEO
AcquisitionUnited KingdomBreaking Updated 30th September 2026 · 06:45
- Significance
- Material
- Impact
- Neutral or Mixed
- Confidence Confidence indicates how reliable ProcIntel considers the event assessment based on the quality, quantity and independence of the supporting evidence. It does not measure the event's importance.
- Low
- Evidence
- 1 source 1 signal
Overview
What happened Source facts
Logo ofDallah Healthcare Co. Dallah Healthcare Co. ‘s board of directors appointed Muteab Altukeas as Chief Executive Officer on Sept. 29, effective Sept. 30, following his tenure as acting CEO. Altukeas holds a master’s degree in project management from Heriot-Watt University in the UK and a bachelor’s degree in civil engineering from King Saud University, according to a statement to Tadawul today, sept. 30. He has more than 15 years of professional and leadership experience across strategy, project management, and mergers and acquisitions. He has served as Chief Strategy Officer at Dallah Health since 2022. From 2017 to 2022, he served as the company’s General Manager of Strategy and Project Management Office. He also has experience serving on boards and committees and overseeing strategic projects and investments. Altukeas holds several professional certifications and has completed a number of executive and specialized programs, including a mergers and acquisitions program at Harvard University, as well as executive and finance programs at London Business School, the statement added. According to data available with Argaam, Dallah Health announced last August the resignation of Ahmed Babaeer as CEO and the appointment of Muteab Altukeas as acting CEO, effective Sept. 1, 2026.
Suggested considerations
Derived from this Event's rating and type — prompts for your team to evaluate, not reported facts and not recommendations.
- Monitor for changes to supplier ownership, contract terms or account relationships.
- Monitor for explicit timing evidence.
- Determine whether internal exposure warrants earlier investigation.
No explicit date was tightly bound to the matched event text, so no occurrence date is claimed.
Suggested Considerations
These are prompts for a procurement team to evaluate, generated from this Event's rating and type. They are not reported facts and not instructions — ProcIntel does not know your contracts, suppliers or exposure.
- Monitor for changes to supplier ownership, contract terms or account relationships.
- Monitor for explicit timing evidence.
- Determine whether internal exposure warrants earlier investigation.
How to read this Event
- Source facts what the original source reported.
- ProcIntel assessment ProcIntel's own interpretation of those facts.
- Consideration a suggested question for your team — never a recommendation to act.
Source Facts
Only what the sources reported. Nothing on this page is ProcIntel's interpretation.
Recorded source facts
Logo ofDallah Healthcare Co. Dallah Healthcare Co. ‘s board of directors appointed Muteab Altukeas as Chief Executive Officer on Sept. 29, effective Sept. 30, following his tenure as acting CEO. Altukeas holds a master’s degree in project management from Heriot-Watt University in the UK and a bachelor’s degree in civil engineering from King Saud University, according to a statement to Tadawul today, sept. 30. He has more than 15 years of professional and leadership experience across strategy, project management, and mergers and acquisitions. He has served as Chief Strategy Officer at Dallah Health since 2022. From 2017 to 2022, he served as the company’s General Manager of Strategy and Project Management Office. He also has experience serving on boards and committees and overseeing strategic projects and investments. Altukeas holds several professional certifications and has completed a number of executive and specialized programs, including a mergers and acquisitions program at Harvard University, as well as executive and finance programs at London Business School, the statement added. According to data available with Argaam, Dallah Health announced last August the resignation of Ahmed Babaeer as CEO and the appointment of Muteab Altukeas as acting CEO, effective Sept. 1, 2026.
This Event rests on a single report. It has not been corroborated by a second, independent source.
-
Dallah Health appoints Muteab Altukeas as CEO
Logo ofDallah Healthcare Co. Dallah Healthcare Co. ‘s board of directors appointed Muteab Altukeas as Chief Executive Officer on Sept. 29, effective Sept. 30, following his tenure as acting CEO. Altukeas holds a master’s degree in project management from Heriot-Watt University in the UK and a bachelor’s degree in civil engineering from King Saud University, according to a statement to Tadawul today, sept. 30. He has more than 15 years of professional and leadership experience across strategy, project management, and mergers and acquisitions. He has served as Chief Strategy Officer at Dallah…
Open original report → argaam.com
Linked Signals
Every collected Signal that contributed to this Event, with how it was matched.
| Published | Headline | Source | Matched text | Extraction confidence | Method |
|---|---|---|---|---|---|
| 30th September 2026 | Dallah Health appoints Muteab Altukeas as CEO | Argaam - Main News | acquisition, merger | 38.5 | keyword combination |
Entities
The real-world companies, places, commodities and organisations this Event involves.
Country 2
- Saudi Arabia reused entity extraction · confidence 95.0
- United Kingdom reused entity extraction · confidence 75.0
Government Organisation 1
- Saudi Exchange (Tadawul) reused entity extraction · confidence 75.0
Locality 1
- London reused entity extraction · confidence 75.0
Full linking detail
| Entity | Type | Link method | Confidence | Source article |
|---|---|---|---|---|
| Saudi Arabia | Country | reused entity extraction | 95.0 | article |
| United Kingdom | Country | reused entity extraction | 75.0 | article |
| Saudi Exchange (Tadawul) | Government Organisation | reused entity extraction | 75.0 | article |
| London | Locality | reused entity extraction | 75.0 | article |
Why ProcIntel Rates This
Every rating below is produced from the logged facts by consistent, rules-based scoring — never from the tone or wording of the source.
Significance Significance estimates the potential procurement impact of the event, including factors such as supply, cost, operations, geography and strategic importance.
3 · Material- This type of disruption typically has a moderate procurement impact.
- A single geography identified so far.
- 1 organisation affected.
- No procurement category has been determined for this event.
- Time horizon is not yet assessed for individual Events; a standard short-term assumption is used.
Confidence Confidence indicates how reliable ProcIntel considers the event assessment based on the quality, quantity and independence of the supporting evidence. It does not measure the event's importance.
2 · Low- Reported only by secondary sources so far — no primary/official confirmation yet.
- Reported by a single source so far — not yet independently corroborated.
- Some key facts (e.g. exact date) are still missing or unconfirmed.
- Evidence was last updated within the last month.
Urgency How soon the evidence already identified for this event suggests action may be needed. Unknown means no sufficiently explicit or quantified timing evidence has been identified -- ProcIntel never infers a timeframe where the evidence does not support one.
UnknownTiming not established. No sufficiently explicit or quantified timing evidence has been identified. Procintel has not inferred urgency where timing evidence is insufficient.
Impact Direction Whether the procurement impact of this development is assessed as negative, positive, or neutral/mixed.
Neutral or MixedProvisional default — not yet reviewed.